Satellite Symposium at the Congress of the International Academy of Pathology
CD30 detection in haematological malignancies: diagnosis and therapeutics
7 October 2014 12:00-13:30
Bangkok Convention Centre at CentralWorld, Bangkok, Thailand
Lotus 1-4

Stefano Pileri, MD, PhD


Stefano Pileri is Professor of Pathological Anatomy and Director of the Haematopathology Service at the University of Bologna, Italy. As of 1 February 2015 he will be Director of the Haematopathology Unit at the European Institute of Oncology in Milan, Italy, and Alma Mater Professor at the University of Bologna.

Professor Pileri received his medical degree from the University of Bologna in 1976, and was awarded a PhD from the University of Kiel in Germany in 1980. He was appointed as Associate Professor of Pathological Anatomy at the University of Bologna in 1986, and took up his current posts in 2001. He has authorized approximately 11,000 diagnoses per year from 1980 until now, with haematopathological biopsy material submitted from 85 different Italian centres.

Professor Pileri has published widely, and is author of 1,049 scientific reports (575 quoted in PubMed and 2 in press in international journals, with a total impact factor of 3406.167). He was co-editor and co-author of the 4th Edition of the WHO Classification of Lymphomas and Leukaemias and co-author of the 1994 Revised European American Lymphoma Classification, and has served on the editorial boards of Leukaemia and Pathologica.He is a regularly invited speaker at international meetings and is a past-president of the European Association for Haematopathology (EAHP). Professor Pileri has received many awards, including an Honoris Causa in Medicine from the University of Athens University in 2011 and the Malpighi Prize in 2012, and he was ranked 42nd among the Italian scientists of the past century on account of his h-index (91).


Stefano Pileri

Koichi Ohshima

Leonard Hwan Cheong Tan

Yok Lam Kwong
This meeting is an
Excerpta Medica activity.
Support for this educational activity is provided by
Takeda Oncology.